perkinelmer-728×90-20191127-1227
K Harish Kumar
Asst. Application Manager – IVD (CLIA) – South India,
Mindray Medical India Private Limited

Latest innovations in immunoassay testing

The global immunoassay analyzer market is majorly driven by an increasing prevalence of different infectious, immunological or metabolic diseases, increasing demand for advanced diagnostic devices, and recent trends of automation and integration, which together have led to the introduction of innovative products in this market.

The global immunoassay analyzers market is expected to grow at a healthy CAGR of 15.6 percent during the forecast period of 2017 to 2023.

Chemiluminescent immunoassay (CLIA) technology permits analytical procedures with lower analyte-detection limits than other immunoassay methods. In other words, CLIA is able to determine the presence of antibodies at extremely low concentrations. Mindray is having a wide range of CLIA analyzers.

Mindray has recently launched CL-900i one of the world’s smallest, fully automated chemiluminescence immunoassay analyzers that integrates a large capacity and fast assay speed into a compact model. It achieves a perfect balance between size and immunoassay-testing performance. With enhanced enzymatic chemiluminescence, patented technology, and Mindray quality heritage, the system guarantees a robust consistence with a higher-end analyzer.

CL-900i is a simple-to-use chemiluminescence analyzer with a throughput of 180 tests per hour. Though in a small benchtop package, it has a large onboard capacity of 15 reagents and 50 samples, and supports non-stop refill of samples, reagents, and consumables during testing. By integrating the reliable CLIA technology with latest electrical and software improvement, CL-900i enables easy operation and brings confident diagnosis faster than ever.

The system combines continuous-access, random-access, and STAT processing with a broad testing menu, allowing medium- and low-volume clinical laboratories to process a variety of immunodiagnostic tests.

CL-900i is designed for both quantitative and qualitative in vitro assay determinations for a broad range of applications; the test menu includes tumor markers, cardiac markers, fertility panel, diabetes panel, anemia panel, bone metabolism parameters, and thyroid markers.

Other unique features of the system include precise 3-phase magnetic separation with consistent performance, environment-friendly solid-liquid waste separation, continuous loading of samples, reagents, and consumables with intelligent inventory management, non-touch vortexer mixing, enhanced washing for sensitive assays, auto-dilution facility, and flexible positions for STAT and priority.

With intelligent sample workflow and high system reliability, CL-900i/CL-960i is a robust and compact immunoassay analyzer, which highly suits the medium- and low-volume clinical laboratories.

Share this:
Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.